SoftOx Solutions AS
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
SOFTX | OL
Overview
Corporate Details
- ISIN(s):
- NO0010811961 (+2 more)
- LEI:
- 549300AETMWJS91G4A50
- Country:
- Norway
- Address:
- Martin Linges vei 25, 1364 Fornebu
- Website:
- https://soft-ox.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
SoftOx Solutions AS is a clinical-stage pharmaceutical company developing a patented, non-toxic antimicrobial technology to address significant global health threats. The company's platform stabilizes a naturally occurring molecule (hypochlorous acid) to create highly effective solutions against a broad spectrum of pathogens, including bacteria, viruses, fungi, and biofilms. A key advantage of this technology is its mechanism of action, which does not contribute to the development of antimicrobial resistance (AMR). The company's primary focus includes an inhalation solution for airway infections, as well as products for advanced wound care and disinfection. SoftOx develops its technology in collaboration with leading scientific and clinical research institutions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-16 12:26 |
Legal Proceedings Report
SoftOx Solutions AS: SoftOx submits Phase 1 Clinical Trial Application under th…
|
English | 2.2 KB | ||
| 2025-10-13 08:11 |
Share Issue/Capital Change
SoftOx Solutions AS: New Share Capital
|
English | 1.7 KB | ||
| 2025-10-07 21:17 |
Share Issue/Capital Change
SoftOx Solutions AS: Private Placement resolved
|
English | 3.0 KB | ||
| 2025-10-03 15:23 |
Share Issue/Capital Change
SoftOx Solutions AS: New Share Capital
|
English | 1.5 KB | ||
| 2025-10-01 14:35 |
Legal Proceedings Report
SoftOx Solutions AS: Clinical Trial Application for Dose Escalation / Cystic Fi…
|
English | 2.6 KB | ||
| 2025-09-25 17:51 |
Share Issue/Capital Change
SoftOx Solutions AS: Clarification on Placement Commission
|
English | 1.5 KB | ||
| 2025-09-25 15:08 |
Share Issue/Capital Change
SoftOx Solutions AS: Private Placements resolved
|
English | 2.0 KB | ||
| 2025-09-23 09:07 |
Regulatory News Service
SoftOx Solutions AS: SoftOx builds momentum: CF trial strategy reinforced by HO…
|
English | 3.6 MB | ||
| 2025-09-23 09:07 |
Regulatory News Service
SoftOx Solutions AS: SoftOx builds momentum: CF trial strategy reinforced by HO…
|
English | 3.0 KB | ||
| 2025-09-23 08:00 |
Regulatory News Service
SoftOx Solutions AS: SoftOx builds momentum: CF trial strategy reinforced by HO…
|
English | 3.6 MB | ||
| 2025-09-23 08:00 |
Regulatory News Service
SoftOx Solutions AS: SoftOx builds momentum: CF trial strategy reinforced by HO…
|
English | 2.4 KB | ||
| 2025-09-17 08:00 |
Interim Report
SoftOx Solutions AS: Second Quarter/Half-Year Report 2025 - Attachment: SoftOx …
|
English | 1.1 MB | ||
| 2025-09-17 08:00 |
Report Publication Announcement
SoftOx Solutions AS: Second Quarter/Half-Year Report 2025
|
English | 367 bytes | ||
| 2025-09-11 15:59 |
Capital/Financing Update
SoftOx Solutions AS: Softox Solutions AS exercises on the financing facility wi…
|
English | 1.9 KB | ||
| 2025-09-08 12:07 |
Investor Presentation
SoftOx Solutions AS: Presentation Deck and link to today's Investor Update - At…
|
English | 3.7 MB |
Automate Your Workflow. Get a real-time feed of all SoftOx Solutions AS filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SoftOx Solutions AS
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SoftOx Solutions AS via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
